1. Biosimilars in the EU. Information guide for healthcare professionals. European Medicines Agency; European Commission, 4 August 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
2. European Generic Medicines Association. Handbook on biosimilar medicines. http://www.bogin.nl/files/ega_biosmilarshandbook.pdf
3. Guidance for industry. Quality consideration in demonstrating biosimilarity of a therapeutic protein product to a reference product. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), April 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
4. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). April 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
5. Guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses (EMEA/CHMP/BWP/398498/2005). London, 24 July 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003795.pdf
6. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process. Non-clinical and clinical issues (EMEA/CHMP/BMWP/101695/2006). London, 19 July 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003935.pdf
7. Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. London: European Medicines Agency, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211640.pdf
8. Guidelines on evaluation of similar biotherapeutic products (SBPs). Annex 2. WHO Technical Report Series No. 977, 2013. http://apps.who.int/medicinedocs/en/d/Js19941en/
9. Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations iI: Biological medicinal products. EMA/168402/2014. 4 August 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211728.pdf
10. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (EMEA/CHMP/BMWP/14327/2006). London: European Medicines Agency, January 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
11. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use (EMA/CHMP/BMWP/86289/2010). London: European Medicines Agency. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf
12. Guideline on similar biological medicinal products (CHMP/437/04). London, 30 October 2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf
13. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005). London, 30 October 2005). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf
14. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMEA/CHMP/BWP/49348/2005). London, 22 February 2006.). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf
15. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) EMEA/CHMP/BWP/247713/2012. London. 22 May 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf
16. Guidelines for assuring the quality of monoclonal antibodies for use in humans. WHO Expert Committee on Biological Standardization. Forty-second report. Geneva: World Health Organization, 1992 (WHO Technical Report Series, No. 822). http://apps.who.int/iris/bitstream/handle/10665/39431/WHO_TRS_822.pdf;jsessionid=31AA9621285F7E7956C3CE5BE4F60F36?sequence=1
17. Guidelines for good clinical practice (GCP) for trials on pharmaceutical product. Annex 3 in WHO Expert Committee on Selection and Use of Essential Medicines. Sixth report. Geneva, World Health Organization. 1995 (WHO Technical Report Series, No. 850). http://apps.who.int/medicinedocs/en/d/Jwhozip13e/
18. Guidelines on evaluation of similar biotherapeutic products (SBPs). WHO Expert Committee on Biological Standardization. Geneva, World Health Organization, 19 to 23 October 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
19. Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. Replacement of Annex 3 of WHO Technical Report Series. No. 814. WHO Expert Committee on biological Standardization, October 2013. http://www.who.int/biologicals/biotherapeutics/rDNA_DB_final_19_Nov_2013.pdf
20. ICH E6 guideline. Guideline for good clinical practice. Geneva, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
21. ICH Q2A guideline. Validation of analytical procedures. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1994. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf
22. ICH Q2B guideline. Validation of analytical procedures: Methodology. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996. https://www.fda.gov/downloads/drugs/guidances/ucm073384.pdf
23. ICH Q5A (R1) guideline. Quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, 1999. https://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm 073454.pdf
24. ICH Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 18 November 2004. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
25. ICH Q6B guideline. Note For Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (CPMP/ICH/365/96). September 1999. http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf.
26. Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95). London, 14 February 1996. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf
27. The impact of biosimilar сompetition. IMS Health, June 2016. http://www.medicinesforeurope.com/wp-content/uploads/2016/08/IMS-Impact-of-Biosimilar-Competition-2016.pdf
28. Weise M., Kurki P., Wolff-Holz E., Bielsky M.-Ch., Schneider Ch. Biosimilars: the science of extrapolation // Blood. 2014. 124. (22). 3191–3196.
29. Биологические препараты. Позиция Российской ассоциации эндокринологов // Сахарный диабет. 2013. (3). 121–122.
30. Василенко И.А. Взаимозаменяемость лекарственных препаратов: сравнительные аспекты // Разработка и регистрация лекарств. средств. 2014. (1). 162–169.
31. Руководство по экспертизе лекарственных средств. Т. I. М.: Гриф и К, 2013. 328 с.
32. Руководство по экспертизе лекарственных средств. Т. III. М.: ПОЛИГРАФ ПЛЮС, 2014. 344 с.
33. Руководство по экспертизе лекарственных средств. Т. IV. М.: ПОЛИГРАФ ПЛЮС, 2014. 172 с.
34. Солдатов А.А., Авдеева Ж.И., Олефир Ю.В., Меркулов В.А., Бондарев В.П. Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов // Биопрепараты. 2016. 16. (2). 78–89.
35. Шаньгин И.В., Смирнов А.С., Шнайдер А.А. Взаимозаменяемость лекарственных препаратов в России: проблемы и перспективы // Соврем. орг. лекарств. обеспечение. 2014. (3). 10–18.